[HTML][HTML] Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - nature.com
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
[HTML][HTML] Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - ncbi.nlm.nih.gov
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - profiles.wustl.edu
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - europepmc.org
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - …, 2016 - pubmed.ncbi.nlm.nih.gov
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
[PDF][PDF] Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - researchgate.net
Prostate cancer (PCa) progression to metastatic disease accounts for> 10% of all cancer-
related deaths in men. Androgen deprivation therapy (ADT) remains the principal treatment …
related deaths in men. Androgen deprivation therapy (ADT) remains the principal treatment …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - go.gale.com
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan… - …, 2016 - mdanderson.elsevierpure.com
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - europepmc.org
Advanced prostate adenocarcinomas enriched in stem-cell features, as well as variant
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
androgen receptor (AR)-negative neuroendocrine (NE)/small-cell prostate cancers are …
[PDF][PDF] Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties
AN Paranjape, R Soundararajan, SJ Werden… - Oncogene, 2016 - researchgate.net
Prostate cancer (PCa) progression to metastatic disease accounts for> 10% of all cancer-
related deaths in men. Androgen deprivation therapy (ADT) remains the principal treatment …
related deaths in men. Androgen deprivation therapy (ADT) remains the principal treatment …